NASDAQ: $SLN A Breakthrough in Gene Silencing In a significant development for cardiovascular medicine, Silence Therapeutics has officially announced positive topline results from their Phase 2 SANRECO clinical trial. The study evaluated divesiran, an innovative investigational treatment designed to address high levels of lipoprotein(a) [Lp(a)]—a known genetic risk factor for cardiovascular disease. Understanding the SANRECO…